Panelists discuss how LEAP-012 trial results show promising progression-free survival, while anticipating further data on overall survival outcomes.
GI Cancer ESMO 2024 Highlights
Panelists discuss how KEYNOTE-811's study design and key findings presented at the European Society for Medical Oncology (ESMO) Congress 2024 demonstrate the potential impact of pembrolizumab plus trastuzumab and chemotherapy in HER2-positive gastric cancer treatment.
Panelists discuss how updates from the POD1UM-303/InterAACT2 trial presented at European Society for Medical Oncology Congress (ESMO) 2024 shed light on retifanlimab’s potential role in advancing treatment options for anal cancer patients.
Panelists discuss how NICHE-2 trial updates offer valuable insights into the role of minimal residual disease assessment in guiding neoadjuvant immunotherapy for colorectal cancer patients.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
ESMO 2026: Survival Gains and New Treatment Strategies in GI Cancers
3
FDA Approves Talazoparib/Enzalutamide in HRR-Mutated Prostate Cancer
4
ADCs Shine, Mixed Bag for Immunotherapy at ESMO 2026 Presidential Symposium III
5